Teva's Buy of Ratiopharm Conditional

Pharmaceutical firm Teva may go ahead with its €3.7 billion takeover of German generic drugmaker Ratiopharm if the companies divest products in the Netherlands and Hungary, the European Commission said on Wednesday.

"The decision is conditional upon the divestment of 15 products in the Netherlands and one in Hungary. The Commission had concerns that the parties' high combined market shares for these products, together with their overall post-merger strength in the Netherlands, could have harmed competition on these markets," the European Union's executive said.

The merger is to reinforce Teva's presence in the world's second-largest generics market. Teva, the world's largest generics drug manufacturer, will also gain a stronger market position in Spain, Italy and France through the deal, which it announced in March.

The combined company would have had revenues of $16.2 billion in 2009. Teva has said that cost savings from the acquisition are expected to amount to at least $400 million within three years of closing the deal.

Teva announced the Commission's decision on Tuesday, but provided no details.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read